期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胃癌个体化化疗 被引量：1

Individualized Chemotherapy in Gastric Cancer
下载PDF
导出
摘要 对于局部晚期或远处转移的胃癌患者化疗具有重要的价值,通过药物基因组学对患者的基因进行检测开出适合每个个体的化学药物的“基因处方”即所谓的个体化化疗无疑将革命性地提高胃癌化疗的效果。现就与胃癌化疗效果密切相关的表达基因TS、DPD、ERCC1等的研究进展予以综述,以更好指导临床肿瘤药物筛选。 Chemotherapy has an important value for those patients with locally advanced or distant metastatic gastric cancer. Individualized chemotherapy,which is the socalled ＂gene prescription＂ that doctom prescribed suitable to individualized chemotherapy drugs by detecting patient genes with pharmacogenomics, will be no doubt to improve the results of gastric cancer chemotherapy. This article reviews many expression genes related to chemo-curative effect of gastric cancer including TS, DPD, ERCCI and so on in order to guide drug screening in clinic oncology.
作者 邓建忠 华东
机构地区 苏州大学第四附属医院肿瘤内科
出处 《医学综述》 2007年第5期352-354,共3页 Medical Recapitulate
关键词 胃肿瘤 药物基因 药物疗法 Gastric neoplasms Drug-related genes Pharmacotherapy
分类号 R735.2 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Lenze HJ,Leichman CG,Danenberg KD,et al.Thymidylate synthase mRNA level in denocarcinoma of the stomach:a predicator for primary tumor response and overall survival[J].J Clin Oncol,1996,14(2):176-182.
  • 2Mattison LK,Soong R,Diasio RB.Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics[J].Pharmacogenomics,2002,3(4):485-492.
  • 3Mcleod HL,Sluden J,Murray GI,et al.Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors[J].Br J Cancer,1998,77(3):461-465.
  • 4van Kuilenburg AB,Haasjes J,Meinsma R,et al.Dihydropyrimidine dehydrogenase(DPD)deficiency:novel mutations in the DPD gene[J].Adv Exp Med Biol,2000,486:247-250.
  • 5Terashima M,Irinoda T,Fujiwara H,et al.Roles of thymidylates and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-Fluorouracil in human gastric cancer[J].Anticancer Res,2002,22(2A):761-768.
  • 6Barry EH,Song R,Soong SJ,et al.Ralationship between dihydropyrimidine dehydrogenase activity and plasma 5-Fluorouracil levels with evidance for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-Fluorouracial by protracted continuous infusion[J].Cancer Res,1990,50(1):197-201.
  • 7Youn CK,Kim MH,Cho HJ,et al.Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents[J].Cancer Res,2004,64(14):4849-4857.
  • 8Metzger R,Leichman CG,Danenberg KD,et al.ERCC1mRNA levels comp lement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy[J].J Clin Oncol,1998,16(1):309-317.
  • 9Hipfner DR,Deely RG,Cole SP.Structural,mechanistic and clinical aspects of MRP1[J].Biochim Biophys Acta,1999,1461(2):359-376.
  • 10Nies AT,Kong J,Pfannschmidt M,et al.Expression of the multidrug resistance proteins MRF2 and MRP3 in human hepatocellular carcinoma[J].Int J Cancer,2001,94(4):492-499.

同被引文献3

引证文献1

医学综述
2007年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部